I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Docket No.: GPCI-P03-185 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Becker et al.

Application No.: 10/820453

Filed: April 7, 2004

Art Unit: 1634

For:

INHIBITORS OF CYCLIN-DEPENDENT

KINASES, COMPOSITIONS AND USES

RELATED THERETO

Examiner: Not Yet Assigned

Confirmation No.: 7279

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

Application No.: 10/820453 Docket No.: GPCI-P03-185

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GPCI-P03-185. A duplicate copy of this paper is enclosed.

Dated: October 12, 2004

Respectfully submitted,

Charles Larsen

Registration No.: 48,533 ROPES & GRAY LLP

One International Place Boston, Massachusetts 02110-2624

(617) 951-7000 (617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/820453 INFORMATION DISCLOSURE April 7, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Becker, et al Art Unit 1634 (Use as many sheets as necessary) Examiner Name Not Yet Assigned 2 GPCI-P03-185 Sheet 1 of Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*		Number-Kind Code ² (if known)	MM-DD-YYYY			
	AA	US-5,593,356	01-14-1997	Takeda		
	AB	US-6,291,504	09-18-2001	Nugiel et al		
	AC	US-6,407,103	06-18-2002	Nugiel et al		
	AD	US-6,413,957	07-02-2002	Nugiel et al		
	AE	US-2003/0165873	09-04-2003	Come et al		
	AF	US-2004/0043388	03-04-2004	Come et al		
	AG	US-2,989,538	06-20-1961	Flores, et al		
-	AH	US-3,211,731	10-12-1965	Schmidt, et al		
	ΑI	US-3,211,732	10-12-1965	Schmidt, et al		
	AJ	US-5,593,997	01-14-1997	Dow, et al		

		FOREI	GN PATENT	DOCUMENTS	_	
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	⊤ 6
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	Ľ
	BA	-WO 99/54308	10-28-1999	Nugiel, et al		
	ВВ	-WO 00/21926	04-20-2000	Markwalder et al		
	BC	-WO 02/067654	09-06-2002	Markwalder et al		
	BD	-WO 02/070662	09-12-2002	Becker, et al		
	BE	-WO 02/34721	05-02-2002	Nugiel et al		
	BF	-WO 02/40182	05-23-2002	Constantini, et al		
	BG	-WO 02/44174	06-06-2002	Yue, Eddy	1	
	ВН	-WO 03/004491	01-16-2003	Carini, David J.		
	BI	-WO 03/063764	08-07-2003	Markwalder, et al		
	BJ	-EP 0203679	12-03-1986	Pasteris, et al		
	BK	-WO 94/13677	06-23-1994	Chen, Yuhpyng, Liang		
	BL	-WO 98/05335	02-12-1998	Lum, et al		
	ВМ	-WO 03/033499	04-24-2003	Bockovich, et al		
	BN	JP-62-099361	05-08-1987	Yoshio, et al		
	ВО	JP-60-130521	07-12-1985	Toshiyasu, et al		
	BP	JP-WO 02/093269	11-21-2002	Ichida, et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	CA	MOSHER, et al; "Benzene Ring Substituted Indeno[1,2-c]pyrazol-4(1H)-ones"; J. Org. Chem, Vol. 35, No. 11, 1970 ppgs 3685 - 3688				
	СВ	NUGIEL, et al; "Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors"; J Med Chem. 2001, 44, 1334 - 1336				

Examiner	Date	
Signature	Considered	

()	Under the Paperwork	c Reduction	on Act of 1995, no persons are re	U.S. Patent and Tra	PTO/SB/08a/b (08-03) pproved for use through 07/31/2006. OMB 0651-0031 idemark Office; U.S. DEPARTMENT OF COMMERCE f information unless it contains a valid OMB control number	
Substitute for form 1449A/B/PTO				Complete if Known		
000	Substitute for form 1445/45/11/10			Application Number	10/820453	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	April 7, 2004	
				First Named Inventor	Becker, et al	
				Art Unit	1634	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	GPCI-P03-185	

C	NUGIEL, et al; "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern"; J Med Chem, 2002, 45, 5524 - 5232
С	YUE, et al; "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3 (1,2)"; J Med Chem 2002, 45, 5233 - 5248
C	SHAW, et al., "Purines, pyimidines and imidazoles"; Chemical Abstracts, vol. 75 no. 1; July 5, 1971, Columbus, Ohio, abstract no. 5837
C	"Protein Kinase Targets: Strategies for Drug Development"; Conference presentation June 10 – 11, 2003; Westin Copley Place Hotel, Boston, MA

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.